Tenon MedicalTNON
Recorded

Tenon Medical 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration16 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Greetings, and welcome to the Tenon Medical Third Quarter 2026 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steve Foster, President and Chief Executive Officer, and Kevin Williamson, Chief Financial Officer. Mr. Foster and Mr. Williamson will present results of operations for the third quarter ended September 30, 2026, and provide a corporate update. A press release detailing these results was released today and is available on the investor relations section of our company's website, www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates, and other information that might be considered forward-looking. While these forward-looking statements represent our current judgment of what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially.

Operator

You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. For a more complete discussion of these factors and other risks, you should review our quarterly and annual reports on file with the Securities and Exchange Commission at www.sec.gov. At this time, I'll turn the call over to Tenon Medical's Chief Executive Officer, Steve Foster.

Steve FosterPresident and CEO

Please go ahead, sir. Thank you, Joe, and good afternoon, everyone.

Steve FosterPresident and CEO

I'm pleased to welcome you to today's third quarter 2026 financial results and corporate update conference call for Tenon Medical. Third quarter revenue was $1.4 million, an increase of 22% over the third quarter of last year, and 12% sequentially from the second quarter. Gross profit was $1 million, an increase of 23% over the prior year period. Gross margin was 66.3%, an improvement of 0.4% compared to the 65.9% a year ago. We delivered this growth while reducing operating expenses compared to both the third quarter of 2025 and the second quarter of this year, improving our loss from operations in the period compared to both prior periods. Looking at the first nine months as a whole, revenue was $4.1 million, an increase of 66% from the $2.5 million in the first nine months of 2025.

Steve FosterPresident and CEO

Gross profit was $2.7 million, more than double the $1.3 million in the prior year period, at a gross margin of 66.2% compared with 54.4%. Growth on the top line came from continued adoption of our Catamaran and SImmetry platforms. We completed more cases with more physician users in the quarter compared to the third quarter of 2025 and Q2 of this year. Physician and distributor training remains a leading indicator for us, with 36 combined training activities completed within the quarter. The improvement in gross margin was primarily driven by two factors: higher revenue, which continues to absorb fixed costs, and the benefit of lower cost of sales within our Catamaran platform, driven by the 510(k) clearance we announced in early Q3, which reclassified certain instrumentation to reusable status. We believe both factors will continue to have positive impact on our gross margins as we continue to grow.

Steve FosterPresident and CEO

Beyond the financials, a few items from the quarter are worth noting. First, on the commercial side, our investments are focused on the commercial aspect of our business. As such, we have introduced a new commercial leader to the organization. Mr. Thomas Batten Jr. joined Tenon as Chief Revenue Officer effective October 1, 2026. Tom brings significant experience in building commercial teams and corporate roles, as well as an independent distributor, with particular expertise in the sacro-pelvic space. We plan to continue adding to our commercial organization under Tom through the hiring of direct sales representatives and onboarding of independent distributor partners as we move forward. This move also allows us to deploy other team members to focus on the important product launches we are planning for through the first half of 2027.

Steve FosterPresident and CEO

On September 30, we announced a full commercial launch of our new titanium 3D-printed lateral screw for the SImmetry+ SI joint fusion system, following a successful limited launch, alpha launch, that generated approximately $1.2 million in revenue from late Q4 2025 through Q3 2026. The new screw is the first component of our next-generation lateral SI joint fusion system. Our two-platform offering continues to progress the way we had planned, with physicians evaluating Catamaran and SImmetry+ as complementary tools, offering inferior-posterior and lateral approaches to the same anatomy. Second, as it relates to our product pipeline, we are progressing on the launches we outlined last quarter. Subsequent quarter end on October 28, we announced the completion of the initial alpha cases of our new Quickstep Decorticator, which is designed to streamline SI joint decortication and simplify the SImmetry+ surgical workflow.

Steve FosterPresident and CEO

We are targeting full market release of Quickstep in the first quarter of 2027. We also anticipate an early December 2026 submission for a highly differentiated enhancement to the SImmetry+ implant. We believe the SImmetry+ platform will deliver differentiated benefits in lateral and oblique procedures with integrated decortication and grafting, combined with threaded implant technology and anti-rotation capabilities. Third, specific to intellectual property, on October 15, we announced that the U.S. Patent and Trademark Office issued eight new patents to the company so far in 2026, bringing our portfolio to 38 issued U.S. patents and nine international patents, with 31 U.S. and foreign patent applications pending. These patents include both system and method claims covering the Catamaran System, and we believe they strengthen our position as an innovator in the sacro-pelvic fusion market. Fourth, as it relates to capital, we significantly strengthened our balance sheet during the quarter.

Steve FosterPresident and CEO

We raised approximately $15.6 million in aggregate gross proceeds through multiple transactions in the quarter. Through the prepayments made in August and September, we repaid our convertible notes in full ahead of the September 11 maturity and regained compliance with Nasdaq stockholder equity requirements, as well as its minimum bid price requirements following our 1-for-35 reverse split in the year. We ended the quarter with $3.8 million in cash and cash equivalents. Looking out over the balance of the year, our priorities remain consistent: expanding physician training and adoption across both platforms, advancing our product pipeline, and maintaining discipline on our spend. With our convertible notes now behind us, our attention is fully on growth. We believe we have multiple ways to win in this market and are excited about what is to come. With that, I will turn the call over to Kevin to discuss our financials.

Kevin WilliamsonCFO

Thank you, Steve. I will now provide a summarized review of our financial results. A full breakdown is available in our press release that crossed the wire this afternoon. Starting with the top line, third quarter revenue was $1.4 million, up 22% from $1.2 million a year ago, and up 12% sequentially from the second quarter of this year. Revenue for the nine months ended September 30, 2026, was $4.1 million, an increase of 66% compared to $2.5 million in the nine months ended September 30, 2025. The increase in the quarter was driven by the continued adoption of our Catamaran and SImmetry systems. Within the quarter, we saw increased procedures and physician users compared to both the third quarter of 2025 and the second quarter of this year.

Kevin WilliamsonCFO

We expect to continue to build on our momentum through recent and upcoming sales force expansion, increased physician and distributor engagement, and future product launches. Gross profit was $1 million, or 66.3% of revenue in the third quarter, compared to $0.8 million, or 65.9% of revenue a year ago, a 23% increase in dollar terms. On a margin basis, we were up about 0.4 percentage points year-over-year. For the nine months, gross profit was $2.7 million, or 66.2% of revenue, compared to $1.3 million, or 54.4% of revenue, a 102% increase in dollars and roughly 11.8 percentage points of margin improvement.

Kevin WilliamsonCFO

The increase in gross margin in the quarter and year-to-date periods was primarily driven by increased revenue, further absorbing fixed costs within our cost of goods sold, while the third quarter also saw benefit from improved Catamaran per-procedure costs, driven by a 510(k) clearance the company announced receiving on July 2nd, which reclasses certain instruments to reusable status. Moving forward, we believe our gross margin will continue to expand as revenue increases and further absorbs fixed costs. Operating expenses totaled $4 million in the third quarter, compared to $4.2 million in the third quarter of 2025. For the nine months, operating expenses totaled $12.4 million, compared to $11.3 million in the prior year period.

Kevin WilliamsonCFO

The decrease in the quarter was primarily due to lower G&A expenses, primarily reflecting lower professional service fees, partially offset by higher sales and marketing expenses, which were associated with increased revenue, and higher R&D expenses as we continue to work towards future product additions. Loss from operations for the third quarter improved by $0.3 million to $3.1 million from $3.4 million in the prior year period. For the nine months, loss from operations improved by $0.2 million to $9.7 million from $9.9 million in the prior period. Net loss was $6.6 million, or $5.39 per share in the third quarter, compared to a net loss of $3.3 million, or $14.17 per share in the third quarter of 2025.

Kevin WilliamsonCFO

For the nine months, net loss was $14.2 million, or $22.48 per share, compared to a net loss of $9.7 million, or $51.72 per share in the same year-ago period. As a reminder, all per-share figures reflect the 1-for-35 reverse stock split we affected on August 10, 2026. The increase in net loss was primarily attributable to non-cash items below the operating line, including $3.1 million of expense related to warrants issued as inducement consideration in connection with our September warrant inducement transaction. And $0.7 million of non-cash interest expense from the amortization of debt discount on our convertible notes, which we repaid in full during the quarter. We ended the quarter with $8.3 million in cash and cash equivalents, compared to $3.8 million as of December 31, 2025.

Kevin WilliamsonCFO

During the quarter, we raised approximately $15.6 million in aggregate gross proceeds and repaid in full our senior convertible notes, which had an aggregate principal amount of approximately $5.16 million ahead of their September 11, 2026 maturity date. This left us with no outstanding debt as of quarter end. Additionally, subsequent to quarter end, we increased our ATM capacity to approximately $7.1 million of availability, which we expect to support our capital needs in the future. Overall, we believe the financial and strategic actions taken during the third quarter, most importantly retiring our convertible notes and strengthening our cash position, have improved our ability to drive continued growth while sustaining a streamlined and disciplined cost base as we fund our commercial, clinical, and development priorities. I'll now hand the call back to Steve for closing comments.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day